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ABSTRACT
Administration of cyclosporine after autologous bone marrow transplantation elicits a T-lymphocyte autoag-
gression syndrome with remarkable similarity to graft-versus-host disease (GVHD). This syndrome, termed
syngeneic GVHD (SGVHD), with both acute and chronic phases, is mediated by a restricted repertoire of
autoreactive T cells that promiscuously recognize major histocompatibility complex (MHC) class II determi-
nants in association with a peptide from the invariant chain (MHC class II–invariant chain peptide; CLIP). This
study evaluated and compared antigen-specific autoreactive T cells during acute and chronic SGVHD ex vivo
isolated with a soluble MHC class II immunoglobulin molecular construct. This approach allows for the direct
assessment of the functional behavior of the effector T cells without potential modification by in vitro culture.
Two major subsets were detected that had overlapping specificity recognizing the MHC class II–binding
domain of CLIP but that were differentially dependent on the N- and C-terminal flanking domains of this
peptide. The N- and C-terminal subsets were primarily associated with acute and chronic SGVHD, respec-
tively. The cytokine profiles of the CLIP-reactive T cells, however, were most informative and closely
correlated with the onset and progression of disease. Levels of type 1 cytokine, particularly interferon-,
messenger RNA (mRNA) production, assessed by quantitative polymerase chain reaction, were dominant
during acute SGVHD, whereas chronic SGVHD was associated with type 2 cytokine mRNA production.
Although there was a dramatic polarization with respect to cytokine production, only subtle changes in antigen
specificity could be detected. Unexpectedly, the functional behavior within the antigen-specific effector cell
populations is not fixed and seems to change as the disease progresses to the chronic phase. Concordant with
the evolution of the effector T-cell response is a differential loss in B7.1 mRNA expression in the N-terminal
CLIP-reactive T-cell subset that may reflect the regulation of this autoimmune response. Of additional
interest, autoreactive T cells producing interleukin-10 mRNA were detected in both acute and chronic
SGVHD, suggesting that this cytokine may play an important but perhaps paradoxical role in both the onset
and progression of this experimental autoaggression syndrome.
© 2004 American Society for Blood and Marrow Transplantation
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aNTRODUCTION
Reconstitution of a functional immune system af-
er bone marrow transplantation (BMT) is complex; it
equires both the generation of a highly diverse T-cell
epertoire and the establishment of tolerance to self-
ntigens. Disruption of this process can lead to imbal-
nce that results in severe immune incompetence or f
B&MTutoaggression [1-3]. In fact, the administration of
yclosporine, a potent immunosuppressive drug, after
utologous or syngeneic BMT paradoxically disrupts
he reconstitution of self-tolerance that leads to active
mmune recognition of self-antigens. Impaired thy-
ic-dependent clonal deletion allows the escape of
utoreactive cells to the periphery, where they mani-
est autoaggression in a permissive environment de-
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5oid of peripheral regulatory mechanisms eliminated
y the BMT preparative regimen [4-8].
The autoimmune syndrome induced by cyclospor-
ne treatment shares pathology similar to graft-versus-
ost disease (GVHD) that occurs after allogeneic
MT [9-12]. The onset of autoaggression, termed
yngeneic GVHD (SGVHD), is characterized by
rythroderma and dyskeratosis. Rapid progression to a
hronic phase can occur, with the development of
brosis and dermal damage [9-12]. Initiation and pro-
ression of SGVHD seem to require distinct autore-
ctive T-cell subsets. The initial onset of acute
GVHD is predominantly associated with CD8 au-
oreactive T lymphocytes; although few, CD4 auto-
eactive T cells can amplify the activity of the CD8
-lymphocyte subset. The development of chronic
GVHD is also dependent on the autoreactive CD4
-cell subset [13-15]. It is unclear whether the CD4
-cell subset acts directly as an effector population or
hether its contribution to chronic SGVHD is lim-
ted to a supportive role for the CD8T lymphocytes.
It is interesting to note that there is a transition
rom a type 1 to a type 2 cytokine response as the
isease progresses to the chronic phase [15]. Analysis
f the autoreactive effector mechanisms in SGVHD
eveals a highly restricted repertoire of CD8 (and
D4) autoreactive T cells that promiscuously rec-
gnize the major histocompatibility complex (MHC)
lass II–invariant chain peptide (CLIP) complex [16-
8]. Moreover, a functional interaction occurs be-
ween the V-region domains of the T-cell receptor
TCR) and the ﬂanking regions of CLIP extending
eyond the MHC class II peptide–binding domain
hat may explain, in part, the TCR restriction and the
romiscuous speciﬁcity of the autoreactive T cells
19-21].
This study evaluated and compared antigen-spe-
iﬁc autoreactive T cells during acute and chronic
GVHD ex vivo isolated with a soluble MHC
sMHC) class II immunoglobulin molecular construct
22]. This approach allows for the direct assessment of
he functional behavior of the effector T cells without
otential modiﬁcation by in vitro culture. The results
uggest that the development and progression of
GVHD are mirrored by a dynamic functional diver-
ence of effector mechanisms. Although there is a
olarization with respect to cytokine production, only
ubtle changes in antigen speciﬁcity can be detected.
nexpectedly, the functional behavior within the an-
igen-speciﬁc effector cell populations is not ﬁxed and
eems to change as the disease progresses to the
hronic phase. Concordant with the evolution of the
ffector T-cell response is a differential loss in cell
urface co-stimulatory receptor expression that may
eﬂect regulation of this autoimmune response. M
92ATERIALS AND METHODS
nduction of SGVHD
Female Lewis rats 4 to 6 weeks of age (Charles
iver Breeding Laboratories, Wilmington, MA) that
eceived syngeneic BMT after total body irradiation
9.5 Gy) were treated daily with cyclosporine 10
g/kg (dissolved in 0.02% ethanol and 5% Emulphor
Rhodia Corp., Cranberry, NJ] in H2O) administered
ubcutaneously for 30 days [4,17]. Acute SGVHD
eveloped within 2 weeks after the untapered with-
rawal of cyclosporine. Acute and chronic SGVHD
ere conﬁrmed by histologic examination of ear,
ongue, and skin.
ffector Lymphocyte Isolation and Target Tissue
ollection
Spleens, peripheral blood, and target tissues
tongue and ear) were harvested from healthy animals
nd from animals with acute and chronic SGVHD.
issue samples were either frozen in liquid nitrogen
r processed for histologic examination. The spleens
ere pushed through a wire mesh screen to obtain a
ingle-cell suspension. Lymphocytes from the spleen
nd peripheral blood were isolated by Ficoll-Hypaque
ensity centrifugation as previously described [15-17].
oluble MHC Class II Immunoglobulin Fusion
roduct
A soluble rat (Lewis) MHC class II/mouse immu-
oglobulin fusion product that maintains the peptide-
inding domain of MHC class II was constructed as
reviously described [23] (Figure 1). Brieﬂy, the ex-
racellular domains of Lewis rat MHC class II  and 
enes were fused to mouse immunoglobulin  and 
hains, respectively. The genes encoding the soluble
himeric sMHC class II immunoglobulin molecule
ere cloned into the pFastBac/Dual vector and the
ac-to-Bac Baculovirus/Sf9 Expression System (Life
echnologies, Gaithersburg, MD) used to express the
olecular construct. The sMHC class II immuno-
lobulin fusion product was puriﬁed by size exclusion
n a Sephacryl 16/60 G-200 column (Pharmacia, Pis-
ataway, NJ). The puriﬁed chimeric construct was also
abeled with the ﬂuorochrome Alexa Fluor 488 or
lexa Fluor 546 (Molecular Probes, Eugene, OR) or
as biotinylated (counterstaining with CyChrome/
treptavidin) as previously described [23].
LIP Peptides and Loading
Truncated variants of rat CLIP containing just
he MHC class II–binding domain or the MHC
lass II–binding domain with either the N- or C-
erminal ﬂanking region (sequences: parent, PKS-
KPVSPMRMATPLLMRPLSMD; C terminal,
RMATPLLMRPLSMD; N terminal, KPVSPM-
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BMATPLLMR; MHC class II–binding domain,
RMATPLLMR) were chemically synthesized and
uriﬁed by high-pressure liquid chromatography by
uality Controlled Biochemicals (Hopkinton, MA)
16,22,23]. Control peptides included MHC class
I–binding peptides from the Her-2/neu oncogene,
n allopeptide (from BN strain rats), or a CLIP
ariant with the ﬂanking domains inverted as pre-
iously reported [16,22,24]. The peptides (92%
urity) were diluted to 10 mol/L in RPMI 1640
edium before the sMHC class II immunoglobulin
onstruct was loaded. Loading of the sMHC class II
mmunoglobulin construct was accomplished in
olar excess by incubating 1 to 10 g of the con-
truct in 10 mol/L of the peptides for 2 hours at
°C. Unbound peptide was removed by size exclu-
ion chromatography.
solation of Antigen-Specific Effector T Cells
The sMHC class II immunoglobulin construct
oaded with peptide was used to isolate antigen-spe-
iﬁc effector T cells as previously described [23].
rieﬂy, splenic T cells or peripheral blood mononu-
lear cells (1-5  106) were stained with conjugated
MHC class II immunoglobulin (1 hour at 4°C) and
ashed 3 times in RPMI 1640. The cells were sorted
n a Becton-Dickinson FACSVantage (Franklin
akes, NJ). The sMHC class II immunoglobulin chi-
igure 1. CLIP autoreactive T-cell subsets. Spleen cells from anim
ssessed for killer-cell activity by using the 3H-thymidine assay [16
arget cells were loaded (displacing natively expressed CLIP) with t
nclude either the N- or C-terminal ﬂanking domains or neither
erminal-ﬂanking domains. Results are expressed as the percentage o
uring acute SGVHD was signiﬁcantly different (P 
 .01, analysis
ssessed during chronic SGVHD. The shaded area, however, repr
etween N- and C-terminal ﬂanking domain dependence.eric molecule loaded with unrelated peptides was [
B&MTneffective in isolating CLIP-speciﬁc T cells [23].
low cytometric multicolor analysis was used to iso-
ate the antigen-speciﬁc T cells and to conﬁrm expres-
ion of the CD4, CD8, and CD25 cell-surface mark-
rs (phycoerythrin- or ﬂuorescein isothiocyanate–
onjugated mouse anti-rat CD8, anti-CD4, and CD25
onoclonal antibodies; Serotec, Harlan Bioproducts
or Science, Indianapolis, IN). Purity was usually
95%. Speciﬁcity was conﬁrmed as previously de-
cribed with isolated CLIP-reactive T cells unable to
ill target cells loaded with the control peptides (Her-
/neu, allopeptide, and CLIP-inverted ﬂanking do-
ains) and by ensuring that cells sorted with irrele-
ant peptides were CLIP-nonreactive T cells [22-24].
NA Preparation
RNA was extracted and puriﬁed with TRIzol (In-
itrogen, Carlsbad, CA) from the lysate of 1 to 5 105
ells with 500 L of TRIzol reagent [23,25]. Tissue
amples were frozen in liquid nitrogen and pulverized
ith a mortar and pestle. The powder was dissolved in
RIzol and centrifuged. The supernatant was col-
ected and extracted with chloroform. RNA was pre-
ipitated with 2-propanol and rinsed with 75% etha-
ol. Puriﬁed RNA was dissolved in 20 L of diethyl
yrocarbonate–treated distilled water. Complemen-
ary DNA was prepared with Ready-to-Go You Prime
irst Strand (Pharmacia) as described previously
h SGVHD were harvested during acute and chronic SGVHD and
efore graded numbers of effector T lymphocytes were added, the
IP variants that, in addition to the MHC class II–binding domain,
n. Untreated target cells express native CLIP that includes both
ﬁc killing 	 SD. The N-terminal CLIP preference of cells isolated
ance) compared with the C-terminal restriction proﬁle of the cells
the effector-target ratio that provides the greatest discriminationals wit
,22]. B
he CL
domai
f speci
of vari
esents22,24].
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5uantitative Reverse Transcriptase-Polymerase
hain Reaction
Quantitative reverse transcriptase-polymerase
hain reaction (PCR) (Taqman; Applied Biosystems,
BI, Foster City, CA) was used to assess levels of
ytokine and cell-surface accessory molecule mRNA
s previously described [24,25]. The oligonucleotide
rimers and ﬂuoresceinated probes for the cytokine
enes (interleukin [IL]-2, IL-4, interferon [IFN]-,
nd IL-10; sequences previously reported) [22-24]
ere purchased from ABI. Oligonucleotide primer
nd probe sequences (purchased from International
NA Technologies, Coralville, IA) for the cell-sur-
ace co-stimulatory molecules B7.1, B7.2, CTLA-4,
nd CD28 are summarized in Table 1. Data were
nalyzed with Sequencer Detection version 1.6 soft-
are (ABI), and the results were normalized against
RNA transcripts for the housekeeping gene glycer-
ldehyde-3-phosphate dehydrogenase and evaluated
y real-time PCR.
ell-Mediated Killing Assay
The 3H-thymidine–based assay (JAM) that mea-
ures DNA fragmentation and cell death was used to
ssess killing activity [15,16,22]. Phytohemagglutinin
ymphoblasts labeled with 2.5 Ci/mL of 3H-thymi-
ine for 18 hours were used as target cells. Peptide
oading was accomplished by incubating the target
ells in 10 mol/L of the peptides for 2 hours at 4°C
ollowed by 3 washes in RPMI 1640 [16,22]. Effector
nd target cells were co-incubated for 4 hours before
arvest. The percentage of speciﬁc killing was deter-
ined as described previously [15,16,22].
solation of Autoreactive Clones
The isolation and establishment of autoreactive
-cell clones with conﬁrmed pathogenic activity from
ewis rats with SGVHD were described in detail
able 1. Oligonucleotide Primers and Probes for Quantitative PCR
Receptor
7.1 Forward
Lower
Probe
7.2 Forward
Lower
Probe
D28 Forward
Lower
Probe
TLA-4 Forward
Lower
Probe
AM indicates 6-carboxyﬂuorescein; BHQ, 6-carboxytetramethyl r
uantitative PCR probes were labeled with the ﬂuors 56FAM andlsewhere [15,16,22]. Brieﬂy, lymphocytes from t
94pleen and peripheral blood from animals with
GVHD were cultured at limiting dilution by using
rradiated (3000 R) syngeneic spleen cells as antigen-
resenting cells in complete tissue culture medium
ontaining IL-2 (10 U/mL). The clones were ex-
anded by re-stimulation every 7 to 10 days with
rradiated syngeneic spleen cells. In addition to con-
rmed pathogenic activity in a local GVHR assay,
revious studies revealed that the vast majority of
-terminal–reactive clones expressed the V 8.5
CR determinant. Conversely, the C-terminal–reac-
ive T-cell clones expressed a variety of V TCR
eterminants, but most of the clones seemed re-
tricted to V 10 TCR gene expression [17,22].
tatistical Analysis
The results were assessed for statistical signiﬁ-
ance by analysis of variance, rank-sum test, or paired
test (SigmaStat; Systat, Richmond, CA).
xperimental Design
SGVHD was induced in Lewis syngeneic BMT
ecipients by the administration of cyclosporine for 30
ays. As revealed in a number of studies, acute
GVHD, characterized by erythroderma and lympho-
yte inﬁltration into the epidermis, with epithelial cell
estruction, develops within 7 to 10 days after the
iscontinuation of cyclosporine treatment [9,10,15].
hronic GVHD begins to develop by day 35 after
essation of cyclosporine treatment and progresses to
omplete alopecia with signiﬁcant ﬁbrosis and dermal
amage. Antigen-speciﬁc T cells were isolated (from
pleens and peripheral blood) from animals with bi-
psy-conﬁrmed acute and chronic SGVHD (days
-14 and 42-56, respectively). The isolated cells were
nalyzed ex vivo to evaluate speciﬁcity, cytokine pro-
le, and expression of classic cell-surface co-stimula-
imers and Probe Sequences
CGCTGCAGGAATCAC-3
AGCAGCAGCACAAAGAGA-3
AM/ACTCCTCGGGTTTCCACGTCTCAGG/3BHQ_2/-3
CTGCCCGTTCACA-3
GGTCCTGCCAAAATACT-3
AM/AGGCTCAAAACATAAGCCCGAGTGAGCT/3BHQ_2/-3
GCTGGTACCCGTCTAC-3
CCGGCTGAAGATGAG-3
AM/TGCTCACCATCACTGCTCTGGATAGGAAA/3BHQ_2/-3
AACCTCACCATCCAAGGA-3
GAGTTCCACCTTGCAGAAG-3
AM/TGAGGGCTGCTGACACCGGACTG/3BHQ_2/-3
in.
_2 in the 5 and 3 positions, respectively.Pr
5-AGC
5-ACC
5-/56F
5-GCC
5-TCC
5-/56F
5-CCG
5-TGG
5-/56F
5-GTG
5-CAT
5-/56F
hodam
3BHQory accessory molecules.
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BESULTS
Assessment of killer-cell activity from animals with
GVHD reveals subsets of autoreactive killer T lym-
hocytes with overlapping speciﬁcity but differential
ependence on the ﬂanking domains of CLIP. As
hown in Figure 1, SGVHD effector lymphocytes
solated during early acute SGVHD effectively killed
arget cells loaded with the CLIP variant that had the
-terminal ﬂanking domain (KPVSP) or target cells
hat expressed native CLIP (both N- and C-terminal
anking domains present). Conversely, killing of tar-
et cells loaded with the MHC class II–binding do-
ain–only variant (without the ﬂanking regions) or
he C-terminal ﬂanking domain (PLSDM) variant was
uch less efﬁcient. Effector lymphocytes harvested
ater during the course of disease (chronic SGVHD)
referentially killed target cells loaded with the C-
erminal domain CLIP variant or the MHC class
I–binding domain or cells that expressed native
LIP. Comparatively, killing of target cells loaded
ith the N terminal was much less effective. Differ-
ntial discrimination of ﬂanking domain dependence
igure 2. Flow cytometric selection of CLIP antigen-speciﬁc T-ce
yclosporine treatment were subjected to 3-color immunoﬂuoresce
mmunoglobulin construct loaded with the N- or C-terminal CLIP v
sothiocyanate (FITC)–and phycoerythrin (PE)–conjugated antibod
he construct is shown in the histogram; the dot plot displays CD8 anf the autoreactive T lymphocytes, however, was t
B&MTreatest at low effector-target cell ratios (gray high-
ighted area, Figure 1). Subsequent studies described
elow used low effector-target ratios to distinguish
etween the CLIP-reactive T-cell subsets.
One potential explanation for the presence of 2
lasses of effector cells is that the acute and chronic
hases of the disease are caused by different antigen-
estricted T-cell populations. Alternatively, patho-
enic subsets may exist within each antigen-restricted
opulation that change over the course of disease.
tudies were undertaken to assess the contribution of
he N- and C-terminal–reactive T cells in acute and
hronic SGVHD isolated ex vivo by using an sMHC
lass II immunoglobulin construct. In addition to
valuating the functional status of cells in vivo, ex vivo
nalysis has the additional advantage of overcoming
he potential selection bias of prior in vitro culture.
Initial studies used 3-color ﬂow cytometry to iso-
ate and characterize N- and C-terminal CLIP-reac-
ive T cells. A representative experiment is shown in
igure 2. Splenic T lymphocytes (harvested on day 14
fter cyclosporine treatment) were stained with bio-
ets. Splenic T lymphocytes harvested on day 14 after cessation of
he cells were stained with the biotinylated soluble MHC class II
(counterstained with CyChrome/streptavidin) and with ﬂuorescein
D8 and CD25, respectively. The percentage of cells staining with
5 expression of the cells reacting with the peptide-loaded construct.ll subs
nce. T
ariants
ies to Cinylated sMHC class II immunoglobulin loaded with
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5he N- or C-terminal variants of CLIP (counter-
tained with CyChrome/streptavidin) and with
uorescein isothiocyanate–conjugated and phyco-
rythrin-conjugated antibodies to the CD8 and CD25
eterminants and were subjected to ﬂow cytometric
nalysis and sorting. Even during acute SGVHD, both
- and C-terminal CLIP-reactive T-cell subsets
ould be detected. Approximately 16% of the lympho-
ytes reacted with the sMHC class II immunoglobulin
oaded with the N-terminal CLIP variant, whereas
0.8% of the population reacted with the molecular
onstruct loaded with the C-terminal CLIP variant.
ost lymphocytes that reacted with the N- or C-
erminal CLIP variant–loaded sMHC class II immu-
oglobulin construct expressed the CD8 cell-surface
ccessory molecule, and approximately 15% of these
ells also expressed CD25. Comparable results were
btained from several different experiments (n  6).
he only differences were minor changes in the pro-
ortions of N- and C-terminal–reactive T cells har-
ested from animals with acute or chronic SGVHD
see below).
The sMHC class II immunoglobulin construct
as used to isolate and functionally characterize the
LIP-reactive T-cell subsets harvested during acute
days 7-14) and chronic (days 42-56) SGVHD. Rep-
esentative results from 1 of several (n  6) experi-
ents are provided in Figure 3. Analysis of the
nfractionated populations consistently revealed dif-
erences in the functional activity of the cells harvested
rom animals with acute or chronic SGVHD. Effector
ymphocytes isolated during the acute phase preferen-
ially killed target cells loaded with the N-terminal
LIP variant or cells that expressed native CLIP that
igure 3. Differential function and speciﬁcity of the CLIP-reactive
nimals with acute and chronic SGVHD (harvested on days 7 a
nfractionated or were separated ﬂow cytometrically on the basis of
ith the N- or C-terminal CLIP variants. Before assay, the cells we
ubsets were assessed for their ability to kill target cells loaded w
ffector-target cell ratio; the results are expressed as the percentage
evels by quantitative PCR normalized against mRNA transcript lev
GAPDH). BD indicates binding domain. ***No mRNA transcriptsncluded the N-terminal ﬂanking domain (assessed at d
96ow effector-target ratios, ie, 12.5:1). Minimal killing
as observed when the target cells were loaded with
ither the C-terminal or the MHC class II–binding
omain–only variants of CLIP. In chronic SGVHD,
owever, the effector lymphocytes preferentially
illed target cells loaded with the C-terminal variant
r target cells that expressed native CLIP (includes
he C-terminal ﬂanking domain). There also was
odest killing of cells loaded with the MHC-binding
omain variant of CLIP (with both ﬂanking domains
bsent). In comparison, the sMHC class II immuno-
lobulin construct loaded with the N- and C-terminal
LIP variants was able to distinguish subsets of effec-
or T cells. It is important to note that on average (n
), the proportional differences in N- and C-terminal–
eactive T cells in acute and chronic SGHVD were
odest (the ratio of N-/C-terminal–reactive T cells
as 1.2-1.4 in acute SGVHD and 0.8-1.0 in chronic
GVHD). There were, however, apparent differences
n the level of activity and the cytokine proﬁle. N-
erminal CLIP-reactive T lymphocytes isolated either
uring acute or chronic SGVHD preferentially killed
arget cells (at a 15:1 effector-target ratio) loaded with
he N-terminal variant of CLIP or target cells that
xpressed native CLIP (includes the N-terminal ﬂank-
ng domain). This subset, however, was unable to
ediate signiﬁcant killing of target cells loaded with
he C-terminal or the MHC class II–binding domain
ariants of CLIP. Conversely, C-terminal CLIP-reac-
ive T lymphocytes effectively killed target cells
oaded with the C-terminal CLIP variant and cells
hat expressed native CLIP (C-terminal ﬂanking re-
ion present). Although comparatively less, signiﬁcant
illing of target cells loaded with the MHC-binding
in acute and chronic SGVHD. Splenic lymphocytes isolated from
respectively, after cessation of cyclosporine treatment) were left
ty with the soluble MHC class II immunoglobulin construct loaded
sively washed in complete tissue culture medium. The lymphocyte
e CLIP variants (3H-thymidine–based killer cell assay) at a 15:1
iﬁc killing 	 SD. The cells were also assessed for cytokine mRNA
he housekeeping gene glyceraldehyde-3-phosphate dehydrogenase
etected. The results of a representative experiment are presented.T cells
nd 42,
reactivi
re exten
ith th
of spec
els for t
were domain CLIP variant was also observed. In contrast,
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Bhis subset was able to mediate only minimal killing of
arget cells loaded with the N-terminal variant. The
roﬁle of killing mediated by the C-terminal CLIP-
eactive T-cell subset isolated either in acute or
hronic SGVHD was similar.
The most pronounced difference among CLIP-
eactive T-cell subsets isolated from animals with
cute and chronic SGVHD was their cytokine proﬁle,
s assessed by quantitative PCR for cytokine mRNA
xpression. A representative experiment is shown in
igure 3. Analysis of the unfractionated population
evealed a complex proﬁle of cytokine mRNA tran-
cript expression. Cytokine mRNA transcripts for
oth IFN- and IL-10 were detected in cells har-
ested from animals with acute and chronic SGVHD.
FN- mRNA transcripts, however, were 100-fold
reater during acute SGVHD, whereas levels of IL-10
ranscripts were marginally increased (2- to 5-fold) in
hronic SGVHD. It is interesting to note that mRNA
ranscripts for IL-4 were detected only in the cells
solated from animals with chronic SGVHD. The
ytokine response in SGVHDwas dissected further by
nalyzing the N- and C-terminal CLIP autoreactive
-cell subsets. IFN- mRNA transcripts were de-
ected in the N-terminal CLIP-reactive T cells iso-
ated from animals with either acute or chronic
GVHD. The levels of IFN- mRNA transcripts de-
ected in the cells harvested during acute SGVHD
ere more than 100-fold greater compared with cells
solated during chronic SGVHD. It is interesting to
ote that IL-10 mRNA transcripts were also detected
n this subset, with levels increased approximately 10-
old when this subset was isolated during chronic
GVHD. IL-4 mRNA transcripts, however, were not
etected in the N-terminal CLIP-reactive subset.
omparatively, differences in active cytokine mRNA
ranscription differed signiﬁcantly in the C-terminal
LIP-reactive T cells isolated during the acute and
hronic phases of SGVHD. C-terminal CLIP-reac-
ive T cells isolated during acute SGVHD had detect-
ble mRNA transcripts only for IFN-. However,
nalysis of the C-terminal CLIP-reactive T-cell sub-
able 2. Assessment of Cytokine mRNA Transcript Levels in CLIP-Re
Cytokine
N-Terminal CLIP Reactive
Acute
SGVHD Chronic S
L-2 98.6 3
FN- 340.7 25
L-4 Not detected Not det
L-10 427.3 104
Splenic effector T lymphocytes from animals with acute and c
peptide-loaded soluble MHC class II immunoglobulin) into N
cytokine mRNA transcripts by quantitative PCR. Data are pre
normal splenic T cells.et isolated during chronic SGVHD revealed marked c
B&MTroduction of mRNA transcripts for both IL-4 and
L-10, whereas IFN- mRNA transcripts were not
etected. Although levels of IL-2 mRNA transcripts
ere not assessed previously, additional studies re-
ealed that transcripts for IL-2, particularly in the
-terminal CLIP-reactive subset, were concordant
ith the detection of IFN-mRNA transcripts (Table
). The differential cytokine and killer-cell proﬁles of
he N- and C-terminal CLIP-reactive T cells in acute
nd chronic SGVHD were consistently (P 
 .01)
bserved in several different experiments (n 4-6). As
ummarized in Table 2, production of type 1 (IFN-,
L-2, and IL-10) cytokine mRNA transcripts was con-
istently increased in the N-terminal CLIP-reactive
-cell subset and exceeded the levels detected in nor-
al T cells (-fold increases were based on comparison
ith normal T cells). It is important to note that
L-10, but not IL-4, mRNA transcripts were detected
n this subset. Conversely, levels of type 2 (IL-10 and
L-4) cytokine mRNA transcripts were principally in-
reased in the C-terminal CLIP-reactive T cells iso-
ated during chronic SGVHD.
The target tissue (tongue) in acute and chronic
GVHD mirrored the activity of the CLIP-reactive
-cell subsets isolated during the different stages of
utoaggression. As demonstrated in Figure 4, type 1
ytokine (IFN- and IL-2) mRNA transcripts were
referentially detected in target tissue harvested dur-
ng acute SGVHD (P 
 .001). Type 2 cytokine (IL-4
nd IL-10) mRNA transcripts were not detected. In
ontrast, tissue analyzed during chronic SGVHD re-
ealed high levels of mRNA transcripts for type 2
ytokines (P 
 .001), whereas mRNA transcripts for
ype 1 cytokines in chronic SGVHD target tissue were
elow the detection levels.
Differences in speciﬁcity and cytokine proﬁles
ere detected in the subsets of CLIP-reactive T cells
epending on whether these were isolated during
cute or chronic SGVHD, as described previously.
he transition of the immune response as SGVHD
rogresses may also reﬂect differential expression of
lassical co-stimulatory cell-surface receptors that are
-Cell Subsets in Acute and Chronic SGVHD*
C-Terminal CLIP Reactive
Acute
SGVHD Chronic SGVHD
17.8 1.4
49.5 0.7
Not detected 75.2
Not detected 641.0
SGVHD were separated ﬂow cytometrically (by using speciﬁc
-terminal CLIP-reactive subsets. The subsets were analyzed for
as the median-fold increase (n  4-6 experiments) compared withactive T
GVHD
.4
.8
ected
.3
hronic
- and C
sentedritically involved in the regulation of the immune
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5esponse, including the type of cytokines produced.
evels of mRNA transcripts for B7.1, B7.2, CD28,
nd CTLA-4, a family of cell-surface co-stimulatory
eceptors and ligands, were assessed in the N- and
-terminal CLIP-reactive T-cell subsets isolated
rom animals with acute and chronic SGVHD. Anal-
sis of mRNA transcript levels has a distinct advantage
n that it may detect the downregulation or differential
xpression of the receptors before their loss at the cell
urface. As demonstrated in Figure 5, mRNA tran-
igure 4. Localized cytokine mRNA transcription in acute and chro
n  3) and chronic (n  3) SGVHD was harvested and analyzed f
ormalized against the mRNA transcript levels for the housekeep
RNA transcript expression was below detectable levels.
igure 5. Expression of cell-surface co-stimulatory ligand/receptor
ymphocytes were harvested from animals with early-onset acute (d
ere separated ﬂow cytometrically on the basis of reactivity with th
-terminal CLIP variants. Preferential N- or C-terminal ﬂanking d
oaded with the truncated CLIP variants. The cells were assessed fo
CR. The results were normalized against levels of GAPDHmRNA
ith acute and chronic SGVHD from 3 separate experiments. GAPDH in
98cript levels for B7.2, CD28, or CTLA-4 in the N-
nd C-terminal CLIP-reactive T-cell subsets isolated
ither during acute or chronic SGVHD were compa-
able. In contrast, there was differential expression of
7.1 mRNA transcripts in the N-terminal CLIP-re-
ctive T-cell subset. B7.1 mRNA transcripts were de-
ected only when the cells were isolated during acute
GVHD. During chronic SGVHD, mRNA for B7.1
as not detected in the N-terminal CLIP autoreactive
-cell subset. Identical results (P
 .01) were obtained
VHD target tissue. Target tissue (tongue) from animals with acute
ls of cytokine mRNA production by quantitative PCR. Results are
e glyceraldehyde-3-phosphate dehydrogenase (GAPDH). ***The
by CLIP-reactive T cells in acute and chronic SGVHD. Splenic
d chronic (day 42) SGVHD. The cells were left unfractionated or
le MHC class II immunoglobulin construct loaded with the N- or
reactivity was conﬁrmed by assessing the ability to kill target cells
B7.2, CD28, and CTLA-4 mRNA transcript levels by quantitative
ipts. Identical results were obtained by analyzing cells from animalsnic SG
or leve
ing genmRNA
ay 7) an
e solub
omain
r B7.1,
transcrdicates glyceraldehyde-3-phosphate dehydrogenase.
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Antigen-Specific T-Lymphocyte Responses in Syngeneic GVHD
Brom 3 additional sets of animals from different exper-
ments with B7.1 mRNA transcripts not detectable in
he N-terminal–restricted subset harvested during
hronic SGVHD.
Studies were undertaken to assess cytokine (IFN-
nd IL-10) and co-stimulatory receptor (CD28,
TLA-4, B7.1, and B7.2) mRNA transcript expres-
ion in T-cell clones with deﬁned speciﬁcity to deter-
ine whether the apparent distinct phenotypes could
e observed at the clonal level. Established clones
epresenting the major SGVHD effector cell pheno-
ypes are shown in Figure 6. Moreover, previous stud-
es revealed that the N-terminal–restricted clones se-
reting IFN- were capable of mediating a local
VHR response, whereas the IL-4/IL-10–producing
-terminal–restricted clones had regulatory activity
ut could mediate pathology consistent with the
hronic phase of SGVHD [15].
The N-terminal–speciﬁc clone (No. 57) effec-
ively killed target cells loaded with the N-terminal
LIP variant or cells that expressed native CLIP (N-
erminal ﬂanking region present). CD28, CTLA-4,
nd B7.2 mRNA transcripts were expressed within
igure 6. Functional and phenotypic analysis of N- and C-term
ymphocyte clones established from animals with SGHVD were as
ariants at a 15:1 effector-target cell ratio; results are expressed as
valuate the clones for cytokine (IFN- and IL-10) and cell-surface
ormalized against glyceraldehyde-3-phosphate dehydrogenase mR
cripts were detected.his subset. However, mRNA transcripts for B7.1, p
B&MTL-4, IL-10, and IFN- were not detected. Another
-terminal CLIP-reactive clone (No. 76) expressed
RNA transcripts for all the co-stimulatory mole-
ules and for IFN-. However, IL-10 mRNA tran-
cripts were not detected. Clone 43 preferentially rec-
gnizes the N-terminal CLIP variant, with minimal
ecognition of cells loaded with the C-terminal CLIP
ariant. It is interesting to note that these cells pro-
uced messages for IL-10 and both B7.1 and B7.2.
he C-terminal–speciﬁc clone (clone 49) preferen-
ially killed target cells loaded with the C-terminal
LIP variant but not cells loaded with the N-terminal
ariant. This subset of effector cells were less efﬁcient
t killing target cells that expressed native CLIP (in-
ludes the C-terminal ﬂanking domain) or loaded with
he CLIP MHC class II–binding domain only. The
NA message for all the co-stimulatory receptors and
or IL-10 was detected while IFN- mRNA tran-
cripts were absent.
Table 3 summarizes the analysis of CLIP-reactive
lone subsets established from animals with SGVHD
uring the transition period from acute to chronic
GVHD. Most N-terminal CLIP-speciﬁc clones ex-
LIP-reactive T lymphocytes in acute and chronic SGVHD. T-
or their ability to kill target cells loaded with the truncated CLIP
rcentage of speciﬁc killing 	 SD. Quantitative PCR was used to
or/ligand (CD28, B7.1, and B7.2) mRNA transcripts. Results were
anscript levels. BD indicates binding domain. **No mRNA tran-inal C
sessed f
the pe
recept
NA trressed mRNA transcripts for IFN- but did not
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6xpress messages for IL-4 and IL-10. This subset of
lones also expressed mRNA transcripts for the B7.1
nd B7.2 co-stimulatory receptors. It is interesting to
ote that in N-terminal–reactive clones, expression of
FN- mRNA transcripts correlated with the absence
f mRNA transcripts for B7.1. The absence of cell-
urface B7.1 was conﬁrmed with ﬂow cytometry by
sing anti-B7.1 monoclonal antibodies (data not
hown). Transcripts for B7.2 mRNA transcripts, how-
ver, were expressed. Comparatively, T-cell clones
hat preferentially killed target cells loaded with the
-terminal variant or target cells expressing native
LIP predominantly expressed mRNA transcripts for
L-4, IL-10, or both. Only 1 C-terminal CLIP-reac-
ive T cell had IFN- mRNA transcripts. All C-ter-
inal CLIP-reactive T-cell clones expressed messages
or B7.1 and B7.2.
ISCUSSION
Previous studies indicate that cyclosporine-in-
uced SGVHD is mediated by a highly conserved
epertoire of autoreactive T cells with promiscuous
ecognition of MHC class II determinants in associa-
ion with CLIP, the invariant chain peptide [16-18].
n this setting, CLIP facilitates the promiscuous rec-
gnition with the N- and C-terminal ﬂanking do-
ains of this peptide (that extend beyond the MHC
lass II peptide–binding groove) functionally interact-
ng with the TCR. Moreover, the interaction of the
LIP ﬂanking regions with the TCR V region deter-
inants may also explain the restriction of the reper-
oire [17].
In SGVHD, there are subtle differences in antigen
peciﬁcity and cytokine production within the im-
une response that parallel the onset and progression
f disease. Analysis of killer-cell activity in these stud-
es reveals 2 major subsets of CD8 effector lympho-
ytes that overlap in their recognition of the MHC
able 3. Clonal Analysis of CLIP-Speciﬁc T Cells*
CLIP
Specificity
No. of
Clones
Cytokine
Production
B7
Expression
IFN- IL-4 IL-10 B7.1 B7.2
-terminal 8     
2     
1     
-terminal 1     
1     
3     
3     
Clones established from animals with SGVHD were analyzed for
killer-cell activity (tested against peptide-loaded target cells) and
for cytokine and B7.1/B7.2 mRNA expression by quantitative
PCR.lass II–binding domain of CLIP (detected at high e
00ffector-target cell ratios) but are differentially depen-
ent on the N- and C-terminal ﬂanking domains of
his peptide (at limited effector-target cell ratios). The
subsets with N- and C-terminal speciﬁcity seem to
referentially segregate with the acute and chronic
hases of SGVHD, respectively. A limited set of
D4 autoreactive T cells also seems to share similar
peciﬁcities [16,17,22].
Mirroring the onset and progression of SGVHD
s the transition of the immune response from type 1
o type 2 cytokines localized at the level of the target
issue. Concordant with these observations are recent
tudies characterizing established T-cell clones from
nimals with SGHVD. Clonal analysis conﬁrms 2
ajor subsets of CLIP autoreactive T cells that are
ifferentially dependent on the N- and C-terminal
anking domains of CLIP [15,18]. It is interesting to
ote that the subsets of cloned effector T cells sepa-
ated on the basis of their requirement for the indi-
idual ﬂanking domains have quite distinct cytokine
roﬁles. Type 1 cytokine mRNA transcripts are pref-
rentially associated with the N-terminal CLIP-reac-
ive T cells, whereas type 2 cytokine mRNA tran-
cripts are predominantly detected in the C-terminal
LIP-reactive clones. The overall activity of effector
-cell populations in acute and chronic SGVHD may
e due to a proportional composition of effector lym-
hocytes that differ in speciﬁcity and function or differ
n their activation status. Similarly, in vitro clonal
nalysis can be quite limited and may not reﬂect the
verall complexity of the effector T-cell response.
These studies used an sMHC class II immuno-
lobulin hybrid construct to identify and functionally
haracterize antigen-speciﬁc T cells ex vivo during
cute and chronic SGVHD. The results clearly con-
rm 2 subsets of predominantly CD8 T cells that
ave overlapping speciﬁcity (ie, mutual recognition of
he MHC class II–binding domain) but with differen-
ial requirements for the N- and C-terminal ﬂanking
omains of this peptide [15,16,23]. Both CLIP-reac-
ive subsets were detected in acute and chronic
GVHD, with modest proportional differences. The
-terminal–reactive T-cell subset is primarily in-
reased in acute SGVHD. In the chronic phase, the
-terminal CLIP-reactive subset is predominant. The
tudies evaluating the subsets for cytokine mRNA
ranscripts are most revealing. Messenger RNA tran-
cripts for IFN-, IL-2, and IL-10 (Figure 3; Table 2)
an be detected in the N-terminal CLIP-reactive T-
ell subset in acute SGVHD, whereas C-terminal–
eactive lymphocytes had only detectable IFN-
RNA transcripts. IL-4 mRNA transcripts, however,
ere conspicuously absent from both subsets isolated
uring acute SGVHD. During chronic SGVHD,
owever, there were substantial changes in the cyto-
ine proﬁles of the CLIP-reactive T-cell subsets. Lev-
ls of mRNA transcripts for IFN- and IL-10 were
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Antigen-Specific T-Lymphocyte Responses in Syngeneic GVHD
Beduced in the N-terminal CLIP-reactive subset. The
ost signiﬁcant changes were detected in the C-ter-
inal CLIP-reactive T-cell subset. IFN- mRNA
ranscripts were not detectable, whereas there were
igniﬁcant levels of IL-10 mRNA transcripts with al-
ost 100-fold increase compared with N-terminal
LIP-reactive cells. Most importantly, mRNA tran-
cripts for IL-4 were detected only in the C-terminal–
eactive subset isolated during chronic SGVHD. The
istinct cytokine proﬁles of both subsets were con-
rmed at the clonal level. Current studies are evalu-
ting whether speciﬁc antigen stimulation can alter
he proﬁle of the responding splenic populations. It is
lso important to note that only a small percentage of
he cells may be secreting cytokines. Studies combin-
ng cell separation with the MHC class II construct
nd intracellular cytokine staining will be informative.
The results clearly suggest that there is a dynamic
volution of the T-cell response in SGVHD, partic-
larly with respect to the cytokine proﬁle. The initial
nset is associated with type 1 cytokine–producing
ells. Progression and development of chronic
GVHD correlates with the downregulation of type 1
ie, IFN-) cytokines and a commensurate upregula-
ion of type 2 (ie, IL-4) cytokines. Certainly, this is
lso reﬂected in the analysis of the acute and chronic
GVHD target tissues that seem to be associated with
ype 1 and 2 cytokine mRNA transcripts, respectively.
Previous studies assessed the pathogenic potential
f the N- and C-terminal CLIP-reactive cells in a
ocal GVHR assay at the clonal level [15,16,23]. The
-terminal CLIP-reactive cells were pathogenic and
ediated histologic changes consistent with an acute
VHR. However, the C-terminal CLIP-reactive T
ells, in addition to having a regulatory function by
nducing downregulation of type 1 cytokine mRNA in
he N-terminal–restricted subset, can induce patho-
ogic changes (including ﬁbrosis) characteristic of
hronic SGVHD. The differential pathogenic and
egulatory potentials of the N- and C-terminal CLIP-
eactive T cells in SGVHD are in accord with the
ndings in other animal model systems. This differ-
ntial pattern of pathogenicity is related to the cyto-
ine proﬁle of the antigen-reactive T cells. Most stud-
es in other model systems suggest that type 1
ytokine–producing cells mediate or accentuate auto-
mmune disease, whereas type 2 cytokine-producing
cells are protective [26-29]. There are similar mech-
nisms involved in acute GVHD after allogeneic
MT: severe histologic damage is associated with type
cytokine production [30-32]. However, the ﬁbrosis
nd dermal damage observed in chronic allogeneic
VHD seem to be related to the local production of
ype 2 cytokines, particularly IL-4 and transforming
rowth factor-. Of note, in previous studies, trans-
orming growth factor- mRNA transcripts were de-
ected in C-terminal CLIP-reactive T cells [15,22,23]. t
B&MTOf additional interest, the results from these stud-
es identify and conﬁrm a distinct subset of N-termi-
al CLIP-reactive cells (conﬁrmed at the clonal level)
n acute and chronic SGVHD that produces signiﬁ-
ant levels of IL-10 mRNA [23]. The detection of this
ubset producing high levels of IL-10 mRNA in acute
GVHD was surprising. Recent clinical studies, how-
ver, indicate that IL-10 may play a signiﬁcant role in
romoting the induction of autologous GVHD [25].
t is interesting to note that although N-terminal
LIP-restricted T cells could be detected inﬁltrating
he tissue, IL-10 mRNA was not detected. This spe-
iﬁc subset of IL-10–producing T cells may remain in
he central lymphoid compartment because of an ab-
ence of the appropriate adhesion molecules that allow
nﬁltration into the tissue. Even though this cytokine
as potent immunoregulatory activities, IL-10 may
lay an unexpected role in SGVHD by augmenting
he survival and proliferation of autoreactive T cells
rematurely released from the thymus [33]. Similarly,
his cytokine can also augment the proliferative re-
ponse of IL-2–and IL-4–activated T cells [34]. The
bility of IL-10 to potentiate immune aggression was
emonstrated recently in an allogeneic GVHD model
35]. In this setting, IL-10 augmented GVHD, pre-
umably through the enhancement of IFN- produc-
ion. Current studies are under way that attempt to
eﬁne the role of this important cytokine in cyclo-
porine-induced autoaggression that may provide im-
ortant insights into autoimmunity, immunoregula-
ion, and the role of IL-10.
Perhaps the most interesting ﬁnding of these stud-
es was the expression of B7.1, B7.2/CD28, and
TLA-4 mRNA transcripts in CLIP-reactive T cells
solated during acute and chronic SGVHD. B7.1
RNA transcripts were not detected in the N-termi-
al CLIP-reactive T cells isolated only during chronic
GVHD. Comparatively, expression of B7.2, CD28,
nd CTLA-4 mRNA transcripts was not affected.
oss of B7.1 mRNA, in fact, may reﬂect the speciﬁc
ownregulation of this responding T-cell subset. Flow
ytometric studies of a population, in this regard,
ould not be revealing because downregulation of
RNA transcription occurs before the loss of the
eceptor at the cell surface. Initial analysis of an N-
erminal clone with this phenotype, however, indi-
ated that B7.1 was not detected at the cell surface as
ssessed ﬂow cytometrically. It is interesting to note
hat the loss of B7.1 mRNA in this subset also corre-
ated with decreasing levels (100-fold) of IFN-
RNA transcripts in the N-terminal CLIP-reactive
ubset isolated during chronic SGHVD. IFN-
RNA transcripts, however, were not completely ab-
ent in this subset isolated during chronic SGVHD,
hus suggesting the possibility that B7.1 is downregu-
ated before the downregulation of IFN- mRNA
ranscript production. Nevertheless, these ﬁndings in-
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6icate that there is ongoing active regulation during
his phase of SGVHD. These results are in accord
ith recent studies demonstrating that the C-termi-
al–reactive lymphocytes induced speciﬁc downregu-
ation of type 1 mRNA transcript production in N-
erminal CLIP-reactive T cells. This family of cell-
urface receptors and ligands is requisite for an
ffective immune response by transmitting a second
ignal that allows complete T-cell activation [36,37].
xpression of B7 on T cells, however, seems to be
irectly involved in immunoregulation and immune
omeostasis via T cell/T cell interactions. The ﬁnding
hat the C-terminal–restricted clones can ameliorate
he pathogenic potential of and cytokine production
y the N-terminal–restricted subset would be consis-
ent with this hypothesis [15,16,23]. Similarly, T
ell/T cell interactions may also lead to the activation
f an effector T-cell subset. Of note, recent studies in
n allogeneic GVHD model suggest that the absence
f B7 expression on T cells leads to the accentuation
f GVHD [38]. B7.2 T cells seemed to play a sig-
iﬁcant role in regulating the immune response
hrough engagement of CTLA-4. Although the re-
ults from these studies are consistent with the down-
egulation of receptors reﬂecting an immunoregula-
ory response, the expansion of a distinct subset
xpressing B7.2, CD28, and CTLA-4, but not B7.1,
annot be excluded. Clonal analysis did reveal a few
-terminal–reactive T-cell clones with this pheno-
ype. Whether this subset is unique in origin or
hether it arises as a result of a speciﬁc immunoregu-
atory response remains unclear. Antigen-speciﬁc
timulation may be required to induce upregulation or
revent downregulation of B7.1—studies that are cur-
ently under way.
In summary, these results indicate that there is a
etwork of effector mechanisms associated with
GVHD that encompasses autoreactive T cells that
verlap in speciﬁcity for the CLIP/MHC class II com-
lex but that are critically dependent on the ﬂanking
omains of the peptide. The cytokine proﬁles of the
LIP-reactive T cells closely correlate with the onset
nd progression of disease. Expression of the mRNA
ranscripts for the cytokines and for the B7/CD28 and
TLA-4 family of co-stimulatory receptors/ligands in
ntigen-speciﬁc T cells reveals that this system is dy-
amic as the disease undergoes transition from acute
GVHD to the chronic phase of disease. Certainly
hese studies provide some new insights into this
nique autoaggression syndrome and raise many new
uestions that are currently under investigation.
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